VetDC Acquires Novel, Targeted Anti-Cancer Drug from Pathway Therapeutics, Inc.

business-wireVetDC, Inc. Acquires Novel, Targeted Anti-Cancer Drug from Pathway Therapeutics, Inc.
VetDC, Inc., today announced that the company has acquired from Pathway Therapeutics, Inc. all rights to Pathway’s investigational class of anti-cancer molecules, including PWT33597 (renamed as VDC-597) and its backup compounds. VDC-597 is a novel, orally available, targeted agent that selectively blocks both PI3-Kinase (PI3K) alpha and mTOR proteins, leading to the inhibition of cancer cell proliferation and cell death. Read the full story on businesswire.com >

0 Comments

Please provide us with the following before posting a comment